Diligence memo · auto-generated · as of July 2, 2026
54Gene, Inc.
54Gene, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
54Gene, Inc. operates in Biotech, based in WASHINGTON, LA, Nigeria; LA, Nigeria. Precision medicine for Africans and the global population
Sub-sector tags: Genomics, biotech.
Capital & rounds (filed)filed
54Gene, Inc. has raised $48M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2021-09-08.
Most recent recorded round closed around 2021-09-08.
Valuation (modeled)modeled
Provath models 54Gene, Inc. at approximately $599M (range $50M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.24× the median modeled value of Series B Biotech companies in 2019–2021 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 4.8 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 98% of Biotech peers (233 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: hC Bioscience, Inc., Trace Genomics, Inc., Debut Biotechnology, Inc., CRISPR Therapeutics AG.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.